Literature DB >> 30526279

Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.

Elizabeth M La1, Sandra E Talbird1, Koren V Kanadanian2, Liping Huang3, Joel Fain4, Amit Srivastava5.   

Abstract

Serogroup B (MenB) is the leading cause of meningococcal disease among 16- to 23-year-olds in the United States and has been responsible for all 10 college outbreaks between 2011 and 2017. Outbreak-associated costs levy a substantial and unforeseen burden on colleges/universities and surrounding communities, in part because they involve collaboration with local and state health departments to develop points-of-dispensing (PODs) outbreak response plans and rapid mass vaccination of a large at-risk student population. The MenB outbreak at Providence College in 2015 was used as a case study to develop an Excel-based Meningococcal Outbreak Cost Calculator that uses target populations for mass vaccination to estimate the costs and resources associated with a meningococcal disease outbreak response. Resources include labor, medical supply, and other nonlabor costs (eg, vaccine-related adverse event costs) over an 18-month period following the outbreak declaration. Based on the actual Providence College population partially or fully vaccinated with MenB-FHbp (Trumenba®, Bivalent rLP2086) (3-dose schedule), the calculator estimated aggregate direct costs of $1,350,963 over 18 months post-outbreak for 4,418 individuals. For planned full vaccination of the enrolled undergraduate population (4,795 individuals), the tool estimated total costs of $1,798,399. In both cases, the majority of costs were for medical supplies (88%-89%) and contract services (7%-9%). This calculator can help to plan a mass vaccination campaign for MenB outbreak control, and underscores the need to vaccinate pre-emptively against diverse disease-causing strains before an outbreak occurs.

Entities:  

Keywords:  College; IMD; MenB-FHBp; costs; outbreak; serogroup B meningococcal disease; vaccine

Mesh:

Substances:

Year:  2019        PMID: 30526279      PMCID: PMC6605861          DOI: 10.1080/21645515.2018.1556074

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  17 in total

1.  The economic burden of sixteen measles outbreaks on United States public health departments in 2011.

Authors:  Ismael R Ortega-Sanchez; Maya Vijayaraghavan; Albert E Barskey; Gregory S Wallace
Journal:  Vaccine       Date:  2013-10-14       Impact factor: 3.641

2.  Adverse Events Following Vaccination With Bivalent rLP2086 (Trumenba®): An Observational, Longitudinal Study During a College Outbreak and a Systematic Review.

Authors:  Theresa M Fiorito; Grayson L Baird; Nicole Alexander-Scott; Suzanne Bornschein; Catherine Kelleher; Nan Du; Penelope H Dennehy
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

3.  Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.

Authors:  Colin W Shepard; Ismael R Ortega-Sanchez; R Douglas Scott; Nancy E Rosenstein
Journal:  Pediatrics       Date:  2005-05       Impact factor: 7.124

4.  Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.

Authors:  Caroline L Trotter; W John Edmunds
Journal:  BMJ       Date:  2002-04-06

5.  Evaluation of Mass Vaccination Clinics in Response to a Serogroup B Meningococcal Disease Outbreak at a Large, Public University-Oregon, 2015.

Authors:  Emily A Fisher; Tasha Poissant; Patrick Luedtke; Richard Leman; Collette Young; Paul Cieslak
Journal:  J Adolesc Health       Date:  2018-08       Impact factor: 5.012

Review 6.  Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements.

Authors:  Federico Martinón-Torres
Journal:  J Adolesc Health       Date:  2016-08       Impact factor: 5.012

7.  Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Amanda C Cohn; Jessica R MacNeil; Thomas A Clark; Ismael R Ortega-Sanchez; Elizabeth Z Briere; H Cody Meissner; Carol J Baker; Nancy E Messonnier
Journal:  MMWR Recomm Rep       Date:  2013-03-22

8.  Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.

Authors:  Jessica R MacNeil; Lorry Rubin; Temitope Folaranmi; Ismael R Ortega-Sanchez; Manisha Patel; Stacey W Martin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-10-23       Impact factor: 17.586

Review 9.  Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.

Authors:  Volker Vetter; Roger Baxter; Gülhan Denizer; Marco A P Sáfadi; Sven-Arne Silfverdal; Andrew Vyse; Ray Borrow
Journal:  Expert Rev Vaccines       Date:  2016-03-04       Impact factor: 5.217

10.  Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016.

Authors:  Heidi M Soeters; Jill Dinitz-Sklar; Prathit A Kulkarni; Jessica R MacNeil; Lucy A McNamara; Elizabeth Zaremski; How-Yi Chang; Eduardo Lujan; Dan Granoff; Melodee Lasky; Barbara Montana
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

View more
  1 in total

1.  Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017.

Authors:  Charles Nuttens; Jamie Findlow; Paul Balmer; David L Swerdlow; Myint Tin Tin Htar
Journal:  Euro Surveill       Date:  2022-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.